Design, conduct, and interpretation of organ impairment studies in oncology patients [3]

Journal of Clinical Oncology

Volumn 24, Issue 21, 2006, Pages 3509-3510

  Takimoto, Chris H ^a   Mita, Alain C ^b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE;

CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; LETTER; ORGAN INJURY; PRIORITY JOURNAL; SUPPLEMENTATION; DIET SUPPLEMENTATION; DRUG ADMINISTRATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY; METHODOLOGY; NOTE; PATHOPHYSIOLOGY; STANDARD;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLOMERULAR FILTRATION RATE; GLUTAMATES; GUANINE; HUMANS; KIDNEY; RESEARCH DESIGN;

EID: 33746844945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6795     Document Type: Letter

References (5)

1. Rahman A, White RM: Cytotoxic anticancer agents and renal impairment study: The challenge remains. J Clin Oncol 24:533-536, 2006
2. Mita AC, Sweeney CJ, Baker SD, et al: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552-562, 2006
3. Takimoto CH, Remick SC, Sharma S, et al: Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol 30:20-25, 2003
4. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
5. Hammond LA, Forero L, Beeram M, et al: Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic cancer. Proc Am Soc Clin Oncol 22:133, 2003 (abstr 532)